Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects

Publisher: John Wiley & Sons Inc

E-ISSN: 1538-7836|13|S1|S323-S331

ISSN: 1538-7933

Source: JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.S1, 2015-06, pp. : S323-S331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

SummaryAntiplatelet agents represent the mainstay of acute coronary syndrome (ACS) therapy to prevent ischemic events and to improve safety in patients undergoing percutaneous coronary intervention. However, despite the availability of several drugs and the use of dual antiplatelet therapy, the pharmacological response is highly variable with a subset of patients continuing to experience recurrent thrombotic events, revealing a wide variability in platelet response to antiplatelet drugs. Several factors may explain this, including genetic variation and environmental factors. Here we look at the application of proteomic analysis, an approach that provides an integrated readout of these diverse influences.